Amendments of the Claims

The following Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-30 (Cancelled)

31. (New) A method of altering the pharmacokinetics of a drug in a subject, comprising:

co-administering with a drug metabolized by a drug-metabolizing mammalian cytochrome p450 enzyme an effective amount of a morpholino antisense oligomer having a backbone composed of phosphorodiamidate linkages, wherein the antisense oligomer blocks expression of the mammalian cytochrome p450 enzyme.

32. (New) The method of claim 31 in which the oligomer has a length of at least 15 nucleotides.

33. (New) The method of claim 31 in which the morpholino antisense oligomer hybridizes to a region of the target RNA molecule that includes the AUG translation start site.

34. (New) The method of claim 31 in which the target RNA is a pre-mRNA and the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an intron-exon boundary or an exon-intron boundary.

35. (New) The method of claim 31 in which the drug induces expression of the mammalian drug-metabolizing cytochrome p450 enzyme.

36. (New) The method of claim 31 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A1, CYP1A2, CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.

37. (New) The method of claim 31 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A2, CYP2B1, CYP2E1, and CYP3A4.

38. (New) The method of claim 31 in which the mammalian cytochrome p450 is CYP3A4.

39. (New) The method of claim 31 in which the mammalian drug-metabolizing cytochrome p450 is a human drug-metabolizing cytochrome p450 enzyme.

40. (New) A method of inhibiting expression of a drug-metabolizing mammalian cytochrome p450 enzyme in a subject, comprising:

administering to the subject an effective amount of a morpholino antisense oligomer having a backbone composed of phosphorodiamidate linkages, wherein the antisense oligomer hybridizes to a target RNA molecule encoding a drug metabolizing mammalian cytochrome p450 enzyme and inhibits expression of the enzyme.

41. (New) The method of claim 40 in which the antisense oligomer has a subunit length of at least 15 nucleotides

42. (New) The method of claim 40 in which the morpholino antisense oligomer hybridizes to a region of the target RNA molecule that includes the AUG translation start site.

43. (New) The method of claim 40 in which the target RNA is a pre-mRNA and the morpholino antisense oligomer hybridizes to a region of the pre-mRNA that includes an intron-exon boundary or an exon-intron boundary.

44. (New) The method of claim 40 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A1, CYP1A2, CYP2A6, CYP2B1, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.

45. (New) The method of claim 40 in which the mammalian cytochrome p450 is selected from the group consisting of CYP1A2, CYP2B1, CYP2E1, and CYP3A4.

46. (New) The method of claim 40 in which the mammalian cytochrome p450 is CYP3A4.

47. (New) The method of claim 40 in which the mammalian cytochrome p450 is a drug-metabolizing human cytochrome p450 enzyme.